|
|
|
|
||
Re: SGMO reminds me a lot of Tesla in the early days This competition is exactly why Sandy wants to get out of liver based gene therapy as quick as possible. DNA,RNAi,mRNA,etc , Everyone will be able to do liver based therapy by 2025 when PKU finally comes out, so developing anything past 2021 may be futile, especially since all the high revenue targets will be taken. Looks like they are smartly starting to head for where they need to be a few years from now.. Away from everyone else towards harder things that others may not be able to do as easily.. Away from the liver.. I do agree that we dont focus on all the competition coming our way soon where we were untouchable before. For example, his year NTLA going to file an IND for gene editing the liver using LNP and CRSPR, and we will just be restarting our own (now one and only) in vivo gene editing trial to liver. |
return to message board, top of board |